Stay updated on Phase II Anti-PD1 Epigenetic Therapy Clinical Trial
Sign up to get notified when there's something new on the Phase II Anti-PD1 Epigenetic Therapy Clinical Trial page.

Latest updates to the Phase II Anti-PD1 Epigenetic Therapy Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe ClinicalTrials.gov record for a completed Phase II study of epigenetic therapy and nivolumab in metastatic non-small cell lung cancer is available, with study details, participant criteria, treatment arms, outcome measures, and study documents.SummaryDifference68%

- Check15 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0; the study page remains a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedA banner announces an NIH website transition, including a notice that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check29 days agoChange DetectedThe footer revision identifier was updated from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer’s site revision number changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check50 days agoChange DetectedThe study details page now displays a 403 Forbidden error, blocking access to the content.SummaryDifference0.5%

Stay in the know with updates to Phase II Anti-PD1 Epigenetic Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase II Anti-PD1 Epigenetic Therapy Clinical Trial page.